Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track

02/13

Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.

The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.

These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1163537536"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163537536\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163537536?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163537536","market":"nz","top_or_hot":-1,"title":"Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report","media":"Stock Track","content":"<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1163537536","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163537536","pubTimestamp":1770993370,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"个股追踪|Vertex Pharmaceuticals财报后多位分析师上调评级盘中飙升5.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}